[Ad hoc announcement pursuant to Art. 53 LR] Transaction in Roche bearer shares

F. Hoffmann-La Roche Ltd

Basel, 10 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Roche Long Term Foundation acquired 540’000 Roche bearer shares at the price determined via an accelerated book building (ABB) process. The Foundation will use these shares to cover current as well as future obligations arising from equity compensation plans. This announcement is based on reports that a member of a shareholder group with pooled voting rights sold 2.7 million Roche bearer shares via this ABB process. Following this transaction, the shareholder group with pooled voting rights owns circa 65% (previously 67.5%) of the issued share capital of Roche.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Hans Trees, PhD Phone: +41 79 407 72 58	Nathalie Altermatt Phone: +41 79 771 05 25
Karsten Kleine Phone: +41 79 461 86 83	Nina Mählitz Phone: +41 79 327 54 74
Dr. Barbara von Schnurbein Phone: +41 79 699 97 44	Sileia Urech Phone: +41 79 935 81 48

Attachment

• 10022023_MR_transaction_en